Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
Eton Pharmaceuticals’ Chief Operating Officer Danka Radosavljevic filed an initial statement of beneficial ownership, detailing equity interests in Eton common stock and equity awards. Reported positions include multiple employee stock options with exercise prices ranging from $1.38 to $15.47 per share and expiration dates between 2027 and 2036, time-vested restricted stock units, and a sizeable performance-based award.
The performance-vested restricted stock unit grant covers 128,985 potential shares and vests in full only if Eton’s common stock closing price reaches or exceeds $72.36 for one trading day on or before July 31, 2029; otherwise, it is forfeited. The filing reflects holdings only and does not report any concurrent purchases or sales.
Eton Pharmaceuticals entered into a material license agreement with Auson Pharmaceuticals for U.S. rights to ASN-001, a late-stage timolol topical gel for proliferating superficial infantile hemangiomas. Eton will pay an upfront license fee of $3.0 million within thirty days and will run a bioavailability bridging study, with plans to submit a New Drug Application in the second half of 2027.
Following FDA approval of ASN-001, Auson is eligible for a $5,000,000 milestone when annual net sales reach $80,000,000 and $10,000,000 when they reach $150,000,000, plus tiered royalties of 10%, 13% and 15% on cumulative lifetime net product sales across specified net sales tiers. A three‑arm Phase II/III trial in 168 patients showed elimination or near-elimination of infantile hemangiomas at week 24 in 56% of twice-daily and 42% of three-times-daily ASN-001 patients, versus 15% with placebo.
Eton positions ASN-001 as a topical therapy complementary to its systemic product HEMANGEOL, targeting an estimated 20,000 to 30,000 U.S. patients within a broader pool of more than 100,000 affected infants annually. If approved, ASN-001 is expected to be the first FDA-approved topical therapy for infantile hemangiomas and benefits from patent protection through 2044.
CASAMENTO CHARLES J reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Charles J. Casamento received a grant of 10,000 performance-vested restricted stock units, each representing one share of common stock. The award vests in full only if the share price reaches $72.36 or higher for one trading day before July 31, 2029, otherwise it is forfeited.
Eton Pharmaceuticals, Inc. reported that Chief Financial Officer Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units under the company's 2018 equity incentive plan. Each unit represents the right to acquire one share of common stock.
The award vests in full only if the closing price of Eton's common stock equals or exceeds $72.36 per share for one trading day at any time before July 31, 2029; if this market condition is not satisfied, the entire award is forfeited without consideration. The filing characterizes the transaction as a grant or award acquisition rather than an open-market purchase.
Erdogan-Trinkaus Ipek reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals granted Chief Commercial Officer Ipek Erdogan-Trinkaus 80,000 performance-vested restricted stock units on July 31, 2026 under its 2018 equity incentive plan. Each unit entitles the holder to one common share if the stock’s closing price reaches $72.36 or higher for one trading day within three years; otherwise the entire award, the only 80,000 shares issuable, is forfeited on July 31, 2029.
BRYNJELSEN SEAN reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals, Inc. granted President & CEO Sean Brynjelsen 128,985 performance-vested restricted stock units under its 2018 equity incentive plan on July 31, 2026.
Each unit represents one common share and vests only if the stock’s closing price reaches at least $72.36 for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without payment on July 31, 2029.
Eton Pharmaceuticals, Inc. reported that Chief Business Officer David Krempa received a grant of 128,985 performance-vested restricted stock units on July 31, 2026 under the 2018 equity incentive plan. Each unit may convert into one share of common stock if the closing price reaches $72.36 per share for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without consideration on July 31, 2029. The 128,985 units represent the maximum and only number of shares issuable under this award.
MAIER PAUL V reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Paul V Maier received a grant of 10,000 performance-vested restricted stock units on July 31, 2026 under the company’s 2018 equity incentive plan. Each unit equals one share and vests in full if the stock’s closing price reaches $72.36 for one trading day before July 31, 2029; otherwise the award is forfeited. After the grant, he holds 10,000 units, the maximum and only number of shares issuable under this award.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Norbert G. Riedel received a grant of 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026 under the 2018 equity incentive plan. Each RSU represents one common share and vests in full if the stock’s closing price reaches $72.36 or higher for one trading day before July 31, 2029; otherwise the entire award is forfeited. Following this grant, Riedel holds 10,000 such units.
Adams Jennifer McKie reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Jennifer McKie Adams received a grant of 10,000 performance‑vested restricted stock units under the 2018 equity incentive plan. Each unit represents one share, vesting only if the stock closes at $72.36 or higher for one trading day before July 31, 2029; otherwise the award is forfeited.